SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1217)9/9/1998 6:46:00 PM
From: Cacaito  Read Replies (1) | Respond to of 1491
 
Ariella, Tamoxifen is sold as Nolvadex by Zeneca, I think they are the ones with the original patent. Barr was the challenger and brought a generic out.

PARS' patented analog, tamoxiphen methiodide, could be used by Zeneca to extend their patent, in agreement with PARS of course.

I think Zeneca is the first candidate to negotiate with PARS for the tamoxifen analog. They are the ones with the big stake in the original.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News